ClinicalTrials.gg
RecruitingNCT07669961Updated Oct 26, 2026

Distraction Cards Versus Emotion-Regulation Toy Squeezing During Intramuscular Vaccination in Preschool Children

An interventional study of Distraction-Card Group and Emotion-Regulation Toy-Squeezing Group in Procedural Pain and Pain-related Fear, sponsored by Mersin University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Mersin University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 26, 2026Primary completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
All
01

Study summary

This single-center, parallel-group, randomized experimental study will compare the effects of two active non-pharmacological interventions - distraction-card use and emotion-regulation toy squeezing - on procedural pain and pain-related fear during intramuscular tetanus vaccination in children aged 4-7 years. Eligible children will be randomized to either the distraction-card group or the emotion-regulation toy-squeezing group. Pain will be assessed using the Wong-Baker FACES Pain Rating Scale, and pain-related fear will be assessed using the Children's Fear Scale before, during, and after the intramuscular injection procedure.

Hypotheses

  • H1a: There is a difference between the groups in mean Wong-Baker FACES scores during the procedure.
  • H1b: There is a difference between the groups in mean Children's Fear Scale scores during the procedure.
Read the detailed description

The study is planned as a single-center, randomized experimental trial with two parallel active intervention groups. The study population will consist of children aged 4-7 years for whom intramuscular tetanus vaccination is planned at Mersin University Hospital.

The sample size was calculated using a priori power analysis based on an effect size of d = 0.714 from Ugucu et al. (2022), with alpha = 0.05 and power = 0.80. The final sample is planned as 68 children, with 34 children in each intervention group.

The Pediatric Vaccination/Injection Unit will be arranged to provide the same environmental conditions for all children and parents, including lighting, temperature, noise level, seating, and procedural workflow. It is decorated with cartoon characters and ornaments. Only one child will undergo the procedure in the room at a time. Routine practice will support parental presence during the invasive procedure. The nurse who performs the intramuscular tetanus vaccination will be the same for both groups and children where feasible and will have pediatric clinical experience.

Before the procedure, children will receive an explanation appropriate to their developmental level, and their physical comfort will be ensured. In the distraction-card group, the child will begin using age-appropriate distraction cards two minutes before the intramuscular injection. The child will be actively engaged with the cards through visual attention and simple developmentally appropriate prompts until the injection procedure is completed. In the emotion-regulation toy-squeezing group, the child will begin squeezing an age-appropriate emotion-regulation toy two minutes before the intramuscular injection and will continue until the procedure is completed.

Pain and pain-related fear scores will be recorded by the researchers two minutes before the procedure, during the procedure at needle insertion/vaccine administration, and one minute after the procedure. Data will be collected during the routinely planned intramuscular tetanus vaccination procedure without delaying or replacing standard clinical care.

Data Collection Instruments The Child Information Form, developed after a literature review, will include variables such as the child's age, sex, previous hospitalization and injection/vaccination experience, previous invasive procedure experience, and the presence and frequency of invasive procedure experience in the last week and in the last month.

The Wong-Baker FACES Pain Rating Scale is a valid and reliable measurement tool used to assess acute pain in children older than three years who can communicate. A score of 0 means no pain, and a score of 10 means unbearable/severe pain. According to scoring, 0-4 indicates mild pain, 5-6 moderate pain, 7-8 severe pain, and 9-10 unbearable pain. The approximate administration time is two minutes. Permission to use the scale should be documented before data collection if required.

The Children's Fear Scale assesses pain-related fear in children. The scale consists of five drawn facial expressions scored from 0 to 4, ranging from a neutral expression (0 = no anxiety/fear) to a fearful face (4 = severe anxiety/fear). Scores of 2 and above are commonly interpreted as high fear in the source methodology. The approximate administration time is two minutes. Permission to use the scale should be documented before data collection if required.

Statistical Analysis Plan Data will be analyzed using a statistical package program. The level of statistical significance will be set at 0.05. The Kolmogorov-Smirnov test will be used to assess the normality of dependent variables. Chi-square tests and tests comparing means will be used to determine group similarity. Appropriate parametric or non-parametric tests will be used to compare between-group and within-group means depending on whether the distribution is normal. If differences are found between group means, an effect size appropriate to the test family will be used.

Randomization and Allocation Concealment Block randomization will be used to preserve balance in participant numbers between groups. The randomization list will be generated by an independent statistician using simple random selection through randomizer.org or equivalent computer-assisted randomization. After block randomization, sequential numbers will be placed in closed opaque envelopes to conceal allocation.

Ethics, Consent, and Assent The study will begin after obtaining ethics committee approval from the Mersin University Health Sciences Research Ethics Committee, written institutional permission from the relevant hospital/unit, written informed consent from parents/legal representatives, and verbal assent from children when developmentally appropriate.

02

Conditions studied

  • Procedural Pain
  • Pain-related Fear

Browse trials for

Keywords

  • child
  • pediatric nursing
  • intramuscular vaccination
  • distraction methods
  • active distraction
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 68 is below the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Mersin University is the lead sponsor of 178 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child aged 4-7 years
  • Child with need or plan for intramuscular vaccination

Exclusion criteria

Exclusion Criteria:

  • Child with a neurodegenerative disease, mental retardation, vision and hearing problems, chronic, life-threatening (sepsis, shock, respiratory / cardiac arrest) or genetic disease
  • Child with use of opioids, narcotics, analgesics or sedatives in the last 24 hours before the procedure
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Distraction-Card Group

    Arm type: Experimental. Behavioral intervention: active distraction-card use. Two minutes before the intramuscular tetanus vaccination begins, the child will start using age-appropriate distraction cards. The child will be actively engaged with the cards through visual attention and simple prompts until the injection procedure is completed.

    Behavioral: Distraction-Card Group

  • Experimental
    Emotion-Regulation Toy-Squeezing Group

    Arm type: Experimental. Behavioral intervention: active emotion-regulation toy squeezing. Two minutes before the intramuscular tetanus vaccination begins, the child will start squeezing an age-appropriate emotion-regulation toy. The toy-squeezing intervention will continue until the injection procedure is completed.

    Behavioral: Emotion-Regulation Toy-Squeezing Group

Interventions

  • BehavioralDistraction-Card Group

    Age-appropriate visual distraction cards suitable for children aged 3-6 years will be used. Cards should be cleanable or single-use according to infection-control practice and should include developmentally appropriate visual content that can maintain the child's attention during the procedure. Two minutes before the intramuscular tetanus vaccination begins, the child will start using age-appropriate distraction cards. The child will be actively engaged with the cards through visual attention and simple prompts until the injection procedure is completed.

  • BehavioralEmotion-Regulation Toy-Squeezing Group

    A safe, age-appropriate, cleanable, medium-firm squeezable emotion-regulation toy appropriate for children aged 3-6 years will be used. The toy should be resistant to tearing and damage and suitable for infection-control procedures between participants if reusable. Two minutes before the intramuscular tetanus vaccination begins, the child will start squeezing an age-appropriate emotion-regulation toy. The toy-squeezing intervention will continue until the injection procedure is completed.

06

What researchers measure

Primary outcomes

  1. Procedural pain score during intramuscular vaccination

    Procedural pain score during intramuscular tetanus vaccination, assessed using the Wong-Baker FACES Pain Rating Scale. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst/unbearable pain. Higher scores indicate greater pain.

    Time frame: during the procedure at needle insertion/vaccine administration

  2. Pain-related fear score during intramuscular vaccination

    Pain-related fear score during intramuscular tetanus vaccination, assessed using the Children's Fear Scale. The scale ranges from 0 to 4, from a neutral/no-fear face to a very fearful face. Higher scores indicate greater fear.

    Time frame: during the procedure at needle insertion/vaccine administration

Secondary outcomes

  1. Pre-procedure pain score

    Pre-procedure pain score assessed using the Wong-Baker FACES Pain Rating Scale. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst/unbearable pain. Higher scores indicate greater pain.

    Time frame: two minutes before intramuscular vaccination

  2. Pre-procedure pain-related fear score

    Pre-procedure pain-related fear score assessed using the Children's Fear Scale. The scale ranges from 0 to 4, from a neutral/no-fear face to a very fearful face. Higher scores indicate greater fear.

    Time frame: two minutes before intramuscular vaccination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Of 141 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 4 months is below that.

Counting every sponsor, half of 141 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jun 25, 2026
StartActual
Jun 27, 2026
Primary completionEst.
Nov 11, 2026was Oct 2026
CompletionEst.
Nov 20, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 7, 2026→Nov 11, 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Oct 7, 2026→Nov 11, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07669961
Lead sponsor
Mersin University
Responsible party
Guzide UGUCU (Principal Investigator, Mersin University) — Principal investigator
First posted
Jun 25, 2026
Start date
Jun 27, 2026
Primary completion
Nov 11, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

GUZIDE UGUCU, RN, MScN, PhD
principal investigator · Mersin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion